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a b s t r a c t
Human cytomegalovirus (HCMV) resides in a latent form in hematopoietic progenitors and undiffer-
entiated cells within the myeloid lineage. Maturation and differentiation along the myeloid lineage
triggers lytic replication. Here, we used peripheral blood monocytes and the monocytic cell line THP-1 to
investigate the effects of 1,25-dihydroxyvitamin D3 on HCMV replication. Interestingly, 1,25-dihydrox-
yvitamin D3 induces lytic replication marked by upregulation of HCMV gene expression and production
of infectious virus. Moreover, we demonstrate that the effects of 1,25-dihydroxyvitamin D3 correlate
with maturation/differentiation of the monocytes and not by directly stimulating the MIEP. These results
are somewhat surprising as 1,25-dihydroxyvitamin D3 typically boosts immunity to bacteria and viruses
rather than driving the infectious life cycle as it does for HCMV. Deﬁning the signaling pathways kindled
by 1,25-dihydroxyvitamin D3 will lead to a better understanding of the underlying molecular
mechanisms that determine the fate of HCMV once it infects cells in the myeloid lineage.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human cytomegalovirus (HCMV) is a β-herpesvirus that
spreads broadly throughout the human population (Sinzger
et al., 2008). In general, about 50–70% of people are serologically
positive for HCMV worldwide (Bate et al., 2010). Although in
immunocompetent individuals HCMV infection is typically asymp-
tomatic, in the case of congenital infection, the virus can cause
severe neurological sequelae such as deafness and developmental
defects following infection of the fetus (Grosse et al., 2008;
Johnson and Anderson, 2014). In immunocompromised indivi-
duals, including those with HIV/AIDS or those receiving organ
transplants, HCMV can cause devastating morbidity and mortality
including pneumonia, retinitis, and transplant rejection (Ljungman
et al., 2011; Paya et al., 2004; Yen et al., 2015). Moreover, many
studies have shown that HCMV can be associated with chronic
diseases such as atherosclerosis and hypertension, cancer, and
autoimmune disease (Dziurzynski et al., 2012; Li et al., 2011;
Streblow et al., 2001; Varani et al., 2009). Therefore, understand-
ing the biology of HCMV infection is both clinically relevant and
intensively studied with regards to potential pharmacological
intervention. Like other herpesviruses, HCMV can establish latency
in the human body, thus making the eradication of the virus from
infected individual a difﬁcult task (Grinde, 2013; White et al.,
2012). The cellular reservoirs for HCMV latency include
hematopoietic stem cells, common myeloid progenitor cells, and
monocytes (Bego and St Jeor, 2006; Goodrum et al., 2002; Sinclair,
2008; Taylor-Wiedeman et al., 1991). Deciphering the mechanisms
that regulate the latent/lytic switch in HCMV infected cells could
lead to the identiﬁcation of novel therapeutics that could be used
to regulate latency. Previous studies have indicated that both viral
and cellular factors are involved in the control of latent and lytic
cycles in myeloid progenitors and monocytes (Chan et al., 2012;
Goodrum et al., 2007; Kew et al., 2014; Keyes et al., 2012b;
O'Connor et al., 2014; Smith et al., 2004; Stevenson et al., 2014);
however, the molecular mechanisms remain unresolved, and it is
highly probable that there are numerous cellular and viral reg-
ulatory factors that have yet to be identiﬁed. In light of this, further
investigation of the mechanisms and factors that inﬂuence the
switch between HCMV latency and lytic replication in clinically
relevant myeloid cell types is needed.
It is known that the developmental maturation of monocytes into
macrophages and dendritic cells can reactivate HCMV from latency
leading to the production of new infectious virus (Chan et al., 2008;
Reeves and Sinclair, 2013; Smith et al., 2004; Soderberg-Naucler et al.,
1997, 2001; Stevenson et al., 2014). In addition, there are various
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extracellular stimuli (i.e. PMA) that can trigger monocyte to macro-
phage differentiation (Greenberger et al., 1980; Hemmi and Breitman,
1985; Huber et al., 2014; Naito, 2008; Nakamura et al., 1986; Netea et
al., 2008) and some of these stimuli have also been shown to directly
induce the HCMV immediate-early gene promoter, which is essential
for induction of the HCMV lytic cycle (Ghazal et al., 1992; Kline et al.,
1998; Stein et al., 1993). Since the activities of these stimuli appear to
be multi-factorial, it is difﬁcult to determine if the major inﬂuence of
these stimuli on lytic replication is induction of the IE promoter,
promotion of cellular maturation/differentiation or a combination of
both activities. THP-1 cells are a monocytic cell line that is commonly
used in combination with primary blood derived monocytes to study
the interaction between HCMV and myeloid cells and gain insight into
the latent/lytic switch (Saffert et al., 2010; Van Damme et al., 2014). It
is well known that HCMV enters latency or a quiescent state in
undifferentiated THP-1, and the virus typically enters into the lytic
cycle after it infects phorbol 12-myristate 13-acetate (PMA) treated
THP-1 cells (Qin et al., 2013; Weinshenker et al., 1988). As a
consequence, PMA is a reagent of choice used to promote myeloid
differentiation in studies aimed at inducing lytic replication in in vitro
systems. However, PMA is a synthetic compound resembling diacyl-
glycerol (DAG) that is capable of activating a broad range of cell
signaling pathways (Castagna et al., 1982; Niedel et al., 1983; Swindle,
Hunt and Coleman, 2002). In this research we sought to identify
additional physiologically relevant compounds that could trigger both
monocyte differentiation and HCMV lytic infection. Vitamin D3 is a
hormone that is produced by the human body and acquired in a
supplemental fashion through diet (Baeke et al., 2010; Holick, 2003;
Lamberg-Allardt, 2006). The most well-known effects of vitamin D3
and its active metabolite 1,25-dihydroxyvitamin D3 are to regulate
homeostasis of calcium and phosphorus and promote bone develop-
ment through interaction with the vitamin D receptor (VDR), a
member of the nuclear receptor family of transcription factors
(Goltzman et al., 2014; Kannan and Lim, 2014). Interestingly, blood
leukocytes robustly express the VDR and results of studies performed
in vitro in human myeloid cell lines and ex vivo in murine bone
marrow cells have demonstrated that 1,25-dihydroxyvitamin D3 has
the ability to induce monocyte–macrophage differentiation (Gemelli
et al., 2008; Hmama et al., 1999; Lagishetty et al., 2011; Liu et al., 2006;
O'Kelly et al., 2002, Bhalla, 1983 #83; Provvedini et al., 1983). It is
therefore not surprising that 1,25-dihydroxyvitamin D3 has been
demonstrated to exhibit antibacterial and antiviral effects (Korf et al.,
2014; Luong and Nguyen, 2011; Maxwell et al., 2012; Spector, 2011).
The importance of 1,25-dihydroxyvitamin D3 in regulation of immune
system function has been further highlighted by studies which suggest
that 1,25-dihydroxyvitamin D3 or synthetic analogs of 1,25-dihydrox-
yvitamin D3 could be used as potent candidates for the treatment for
autoimmune diseases, infectious diseases and anticancer therapies
(Salomon et al., 2014; Yuzefpolskiy et al., 2014; Zhang et al., 2013).
Nonetheless, the effect of 1,25-dihydroxyvitamin D3 on HCMV repli-
cation in monocytes and macrophages remains unknown. Therefore,
we explored the possibility that peripheral blood monocytes and THP-
1 cells could be used to determine the effect of 1,25-dihydroxyvitamin
D3 on HCMV replication in myeloid cells. According to the results of
previous studies, 1,25-dihydroxyvitamin D3 treatment induces THP-1
cells to differentiate into mature monocytes, with high CD14 expres-
sion (Daigneault et al., 2010; Hmama et al., 1999; Schwende et al.,
1996) and therefore we also hypothesized that we also could use this
model to study HCMV replication in 1,25-dihydroxyvitamin D3 treated
cells that are in the transition from the promonocytic to macrophage
stages.
Interestingly, we found that the HCMV lytic phase can be
induced in 1,25-dihydroxyvitamin D3 treated primary monocytes
and in THP-1 cells with infectious virus being produced by these
cells. In contrast to PMA treated cells, 1,25-dihydroxyvitamin D3
does not have a direct effect on the HCMV immediate-early gene
promoter in reporter gene assays suggesting that the predominant
effect of 1,25-dihydroxyvitamin D3 is to drive differentiation and
not necessarily to directly stimulate IE promoter activity. When
1,25-dihydroxyvitamin D3 is combined with PMA to differentiate
THP-1 cells, no additive effect on HCMV replication is observed.
These results demonstrate that 1,25-dihydroxyvitamin D3 induces
a set of differentiation related signaling pathways that creates a
favorable cellular milieu for HCMV lytic infection. Moreover, our
results suggest that clinical/dietary supplementation with vitamin
D3 could be problematic in patients susceptible to reactivation-
based HCMV disease.
Results
1,25-dihydroxyvitamin D3 promotes HCMV replication in primary
monocytes and THP-1 cells
Vitamin D3 is a natural hormone that is produced by human
body and typically supplemented through diet (Baeke et al., 2010;
Holick, 2003; Lamberg-Allardt, 2006). In addition to the regulation
of the homeostasis of calcium and phosphorus (Garabedian and
Ulmann, 1979; Goltzman et al., 2014), vitamin D3 has been shown
to play multiple roles in immune responses including modulating
T cell and B cell activity (Terrier et al., 2012), promoting monocyte–
macrophage differentiation (Pan et al., 1997; Takahashi et al.,
1997), stimulating the anti-bacterial and anti-viral effects of
macrophages (Campbell and Spector, 2012; Verway et al., 2013),
and driving lineage commitment of hematopoietic progenitor cells
(Bunce et al., 1997). Vitamin D3 like other endocrine hormones is
carried by the circulatory system to various tissues (Baeke et al.,
2010), and research has also shown that many cells within the
immune system have the enzyme that can convert Vitamin D3 into
its active form, 1,25-dihydroxyvitamin D3 (Ooi et al., 2014;
Shahijanian et al., 2014; Stoffels et al., 2006). Therefore, vitamin
D3 can execute its effects on a wide variety of cells in either an
endocrine or paracrine fashion (Hewison, 2012). HCMV is a β-
herpesvirus which can infect myeloid cells and establish latent
and/or lytic infections within cells of this lineage (Sinclair, 2010).
Although studies have shown that allogeneic stimulation or
stimulation with cytokines like TNF-α can stimulate HCMV IE
promoter activity and drive lytic replication in myeloid cells
(Prosch et al., 1995; Soderberg-Naucler et al., 1997; Stein et al.,
1993), the effect of 1,25-dihydroxyvitamin D3 on HCMV replica-
tion in myeloid cells remains unexplored. To determine if 1,25-
dihydroxyvitamin D3 may inﬂuence HCMV lytic replication in
myeloid cells, we examined the effect of 1,25-dihydroxyvitamin D3
on the ability of CD14 positive peripheral blood monocytes to
support lytic replication. Peripheral blood mononuclear cells
(PBMCs) from healthy anonymous donors were isolated by
Ficoll-paque and CD14 positive monocytes were subsequently
isolated from PBMCs using CD14 magnetic beads (Miltenyi).
Monocytes were treated with 1,25-dihydroxyvitamin D3
(100 nM) for 2 days and infected with HCMV TB40E at an MOI of
10. On days 4 and 6 post-infection, cells were harvested and
subsequently co-cultured with human foreskin ﬁbroblasts (infec-
tious center assays) to determine whether the infected monocytes
were producing infectious virus. Interestingly, monocytes treated
with 1,25-dihydroxyvitamin D3 exhibited a 5–8 fold increase in
infectious centers over cells treated with the vehicle control
ethanol (Fig. 1A). These data indicate that 1,25-dihydroxyvitamin
D3 treatment can create a milieu in blood monocytes that more
efﬁciently supports HCMV virus production. HCMV replication in
primary monocytes treated with the phorbol ester phorbal 12-
myristate 13-acetate (PMA) was similarly examined (Fig. 1B). PMA
is a well-established inducer of HCMV replication in a number of
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systems (Qin et al., 2013; Weinshenker et al., 1988). PMA treated
cells exhibited a 15–30 fold increase in infectious centers over cells
treated with the vehicle control DMSO (Fig. 1B). Thus, for compar-
ison, while it is readily apparent that 1,25-dihydroxyvitamin D3 is
a robust inducer of HCMV replication in monocytes, the level of
replication achieved is not as strong as that achieved by the
phorbol ester, consistent with what might be expected for a
natural compound like 1,25-dihydroxyvitamin D3.
We then sought a model system that could be utilized to
provide a more mechanistic explanation for this ﬁnding. THP-1, an
established monocytic cell line and model system frequently used
in HCMV studies (Keyes et al., 2012a; Saffert et al., 2010), was then
deployed to further explore the effects of 1,25-dihydroxyvitamin
D3 on HCMV lytic replication. Since it is well established that PMA
can drive HCMV production in THP-1 cells, we again used PMA as a
control in these experiments (Weinshenker et al., 1988). THP-1
cells were treated with vehicle (ethanol), 1,25-dihydroxyvitamin
D3 (100 nM) or PMA (80 nM) for 3 days before infection. Cells
were then infected with HCMV TB40E at an MOI of 10. On day
6 post-infection, THP-1 cells were co-cultured with HFFs in
infectious center assays. In THP-1 cells treated with the ethanol
control, only a very low number of plaques were detected in
infectious center assays, which indicate that THP-1 cells rarely
support lytic phase replication after HCMV infection (Fig. 2). In
PMA treated THP-1 cells, there was a 40-fold increase in the
number of plaques arising in infectious center assays supporting
early studies that reported the induction of lytic phase replication
by PMA treatment. Importantly, 1,25-dihydroxyvitamin D3 treat-
ment of THP-1 cells resulted in a 10-fold increase in the number of
plaques arising in infectious center assays. We repeated this
experiment and examined infectious center production at days
6 and 8 post-infection and obtained similar results, indicating that
the difference in lytic replication observed between 1,25-dihy-
droxyvitamin D3 and PMA treated cells is not simply the result of a
delay in virus replication in the 1,25-dihydroxyvitamin D3 treated
cells (data not shown). Therefore, since 1,25-dihydroxyvitamin D3
can promote lytic virus production in both peripheral blood
monocytes and in the monocytic cell line THP-1, we conclude that
THP-1 cells would provide a viable model to recapitulate and
further explore the effects of 1,25-dihydroxyvitamin D3 on HCMV
replication in myeloid cells.
1,25-dihydroxyvitamin D3 treatment does not inﬂuence the ability of
HCMV to establish an initial infection in monocytes
Since we found that 1,25-dihydroxyvitamin D3 treatment can
dramatically increase the number of plaques that arise from THP-1
cells in co-culture infectious center assays, we wanted to deter-
mine whether this difference could be the result of increased
infectivity or entry of HCMV virions into 1,25-dihydroxyvitamin
D3 treated cells. We used semi-quantitative PCR to examine viral
genome copy number in cells at various time points post-infection
(Fig. 3). If 1,25-dihydroxyvitamin D3 leads to increased infectivity
of the monocytes, we would expect to see increased viral DNA
levels at early time points post-infection. However, at day 1 post-
infection, cells treated with 1,25-dihydroxyvitamin D3 or PMA
exhibited similar viral copy numbers to that of vehicle control
cells. The results are depicted in Fig. 3A and quantitative results
from six independent experiments are shown in Fig. 3B. This result
suggested that HCMV infects control and 1,25-dihydroxyvitamin
D3 treated cells with equivalent efﬁciency. At day 6 post-infection,
the PCR signal for viral genomes in control THP-1 cells declined
while the signal from 1,25-dihydroxyvitamin D3- and PMA-treated
cells was maintained or increased, consistent with the conclusion
that 1,25-dihydroxyvitamin D3 and PMA treated cells are support-
ing lytic HCMV replication.
1,25-dihydroxyvitamin D3 treated THP-1 cells are more likely to
exhibit IE gene expression following infection
While an equivalent amount of HCMV DNA is initially present
following infection of control or 1,25-dihydroxyvitamin D3 treated
cells, it is clear that the 1,25-dihydroxyvitamin D3 treated cells support
a robust increase in productive HCMV replication. Therefore, we next
chose to examine HCMV gene expression proﬁles in 1,25-dihydrox-
yvitamin D3 and PMA treated cells. Immediate early (IE) gene expres-
sion is typically repressed in cells that fail to undergo lytic phase
induction, but is expressed rapidly after infection in cells capable of
supporting lytic replication (Keyes et al., 2012a; Meier, 2001; Turtinen
Fig. 1. 1,25-dihydroxyvitamin D3 promotes HCMV replication in primary peripheral blood derived monocytes. Monocytes were treated with 100 nM 1,25-dihydroxyvitamin
D3 (A) or 80 nM PMA (B) for 2 days and then infected with HCMV TB40E at a MOI of 10. On 4 days and 6 days post- infection, cells were harvested and co-cultured with HFF
ﬁbroblasts for 2 days. After 2 days of co-culture, ﬁbroblast monolayers were overlayed with CMC/MEM and incubated for 8 days to allow for plaque development. The data
represent 4–8 independent experiments performed in duplicate. VitD3, 1,25-dihydoxyvitamin D3. npo0.05, nnpo0.01.
Fig. 2. 1,25-dihydroxyvitamin D3 promotes HCMV replication in the THP-1 mono-
cytic cell line. THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3
(100 nM) or PMA (80 nM) for 3 days and then infected with HCMV TB40E at a MOI
of 10. On day 6 post-infection, cells were harvested and co-cultured with HFF
ﬁbroblasts for 2 days. After 2 days of co-culture, ﬁbroblast monolayers were
overlayed with CMC/MEM and incubated for 8 days to allow for plaque develop-
ment. The data represent ﬁve independent experiments performed in duplicate.
VitD3, 1,25-dihydoxyvitamin D3. nnpo0.01, nnnpo0.001.
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and Seufzer, 1994). We examined IE gene expression in cells treated
with vehicle control, 1,25-dihydroxyvitamin D3 or PMA (Fig. 4). Flow
cytometric staining with anti-IE-Alex488 antibodies was performed as
this enabled us to assess not only the frequency with which IE positive
cells arise but also the relative level of IE antigens per cell. Infected cells
were harvested and examined at day 1 post-infection. Compared to
vehicle control, 1,25-dihydroxyvitamin D3 treatment resulted in a
signiﬁcantly higher percentage of IE positive cells by day 1 post-
infection (Fig. 4A and B). Interestingly, while the number of IE positive
cells is signiﬁcantly increased with 1,25-dihydroxyvitamin D3 treat-
ment, there is no difference in the relative IE expression per cell as the
mean ﬂuorescent intensities are similar when comparing vehicle and
1,25-dihydroxyvitamin D3 treated cells (Fig. 4C). PMA, in contrast,
caused an increase in both the percentage of IE positive cells and
relative IE expression per cell, suggesting that the mechanisms utilized
by 1,25-dihydroxyvitamin D3 and PMA to promote lytic replication
may be distinct. We did not detect any differences in the subcellular
localization of IE1/2 when comparing control, 1,25-dihydroxyvitamin
D3, and PMA treated cells indicating that changes in the compartmen-
talization of IE proteins is unlikely to account for the mechanism of
1,25-dihydroxyvitamin D3 induced HCMV replication (data not
shown).
Taken together, while viral genome copy numbers are initially
equivalent, the 1,25-dihydroxyvitamin D3 treated cells are more highly
likely to be capable of initiating IE protein production consistent with
their ability to progress to the lytic phase (Figs. 2 and 4). Moreover,
while 20–40% of THP-1 cells treated with 1,25-dihydroxyvitamin D3 or
PMA express IE antigens, it is evident that not all cells that progress
through the IE phase go on to produce infectious virus based on
infectious center assays, indicating that there are additional blocks
subsequent to IE expression that control the progression to the lytic
phase in HCMV infected myeloid cells.
HCMV early and late genes are expressed in 1,25-dihydroxyvitamin
D3 stimulated cells
Although IE expression is important for initiation of lytic
infection, the expression of early and late genes are needed to
complete the lytic phase (McDonough and Spector, 1983; Wathen
and Stinski, 1982). Therefore, the expression of early and late
HCMV genes was examined by western blot in vehicle control,
1,25-dihydroxyvitamin D3 and PMA treated cells (Fig. 5A and B).
For these experiments, we analyzed UL44, a processivity factor
associated with the viral DNA polymerase (Sinigalia et al., 2008),
which is expressed with delayed-early kinetics (Hwang et al.,
2000) and pp65, a tegument protein that is expressed with late
kinetics (Kalejta, 2008). Vehicle control infected cells exhibited
undetectable levels of either the delayed early UL44 or late pp65
proteins while cells treated with 1,25-dihydroxyvitamin D3 or
PMA prior to infection showed dramatic upregulation of both
UL44 and pp65. Representative western blots are depicted in
Fig. 5A and the results are depicted graphically in Fig. 5B in which
the blots were quantitated and viral protein levels are shown
relative to the cellular actin protein as a control. To further
investigate viral gene expression patterns in these cells and
determine what percentage of IE positive cells progress to the
early phase as evidenced by UL44 expression, cells at days 1 and 4
post-infection were co-stained for IE1/2 and UL44 expression and
analyzed by ﬂow cytometry (Fig. 5C). In vehicle treated cultures,
about 7.5% of the cells were IE positive at day 1 post-infection,
while the percentage of IE positive cells dropped to 4.4% at day 4
post-infection. Of the 4.4% IE positive cells at day 4 post-infection
only 11% of cells were UL44 positive (0.5% of the total cellular
population). In 1,25-dihydroxyvitamin D3 treated cultures, appro-
ximately 33% of the cells were IE positive at day 1 post-infection,
Fig. 3. 1,25-dihydroxyvitamin D3 treatment does not inﬂuence the ability of HCMV
to establish an initial infection. (A) THP-1 monocytes were treated 1,25-dihydrox-
yvitamin D3 (100 nM) or PMA (80 nM) for 3 days and then infected with HCMV
TB40E at a MOI of 10. On days 1 and 6 post-infection, DNA from THP-1 cells
subjected to the indicated treatments was ampliﬁed by PCR for HCMV genomes (IE
region) or cellular genomes (GAPDH). PCR products were visualized by agarose gel
electrophoresis. (B) The PCR signals of viral DNA were normalized to the signals of
GAPDH. Data shown are the means7SEM of six independent experiments. VitD3,
1,25-dihydroxyvitamin D3. n.s. non-signiﬁcant, npo0.05, nnpo0.01, d.p.i. day post-
infection.
Fig. 4. 1,25-dihydroxyvitamin D3 treatment increases the percentage of cells
supporting HCMV IE gene expression. (A) THP-1 monocytes were treated with
1,25-dihydroxyvitamin D3 (100 nM) or PMA (80 nM) for 3 days and then infected
with HCMV TB40E at a MOI of 10. At 1 day post-infection, cells were ﬁxed,
permeabilized and stained with anti-HCMV IE antibody mAB 810-Alexa488. Cells
were analyzed by ﬂow cytometry. (B) The percentage of IE positive cells at day
1 post-infection is presented graphically. The data are derived from four indepen-
dent experiments including the one depicted in panel A. (C) The mean ﬂuorescence
intensity of IE positive cells at day 1 post-infection is presented graphically. The
data are derived from four independent experiments including the one depicted in
panel A. VitD3, 1,25-dihydroxyvitamin D3. nnpo0.01, nnnpo0.001.
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while the percentage of IE positive cells declined to 19% at day 4
post-infection. However, of the 19% IE positive cells, 33% were
UL44 also positive (6.5% of the total cellular population). In PMA
treated cultures, 40% of the cells were IE positive at day 1 post-
infection and the percentage decreased slightly to 38% at day 4
post-infection. Of the 38% IE positive cells, 48% were also UL44
positive (18% of the total cellular population). The results of these
early and late gene expression proﬁling experiments are also in
line with the results of infectious center assay and are all
consistent with the conclusion that 1,25-dihydroxyvitamin D3
promotes HCMV lytic replication in myeloid cells.
1,25-dihydroxyvitamin D3 uses a mechanism distinct from that of
PMA to promote lytic replication
Due to the fact that both 1,25-dihydroxyvitamin D3 and PMA
can prime THP-1 cells to support lytic infection, it would be
intriguing to determine if these two reagents deploy the same
mechanism or if 1,25-dihydroxyvitamin D3 functions in a manner
distinct from that of PMA. Moreover, since it is clear that IE protein
expression is critical for the onset of lytic replication, we wished to
investigate the effects of 1,25-dihydroxyvitamin D3 and PMA on IE
gene expression in a more detailed manner. Based on published
reports (Abraham and Kulesza, 2013), it has been demonstrated
that the HCMV IE enhancer region in THP-1 cells after infection is
marked by histone 3 lysine 27 trimethylation (H3K27me3), and
that the H3K27me3 mark at the IE enhancer is signiﬁcantly
decreased after PMA treatment. H3K27me3 is associated with a
closed chromatin conformation and silenced gene expression (Fu
et al., 2014), therefore it appears that decreased H3K27me3 in the
IE region correlates with an open chromatin conformation and
increased MIEP activity. We wanted to determine whether
H3K27me3 associated with the IE enhancer is also decreased in
1,25-dihydroxyvitamin D3 treated cells. Using chromatin immu-
noprecipitation (CHIP) followed by PCR for the IE enhancer region,
we ﬁnd that the IE enhancer region in control cells is in fact
modiﬁed by H3K27me3 as reported by others (Fig. 6A) (Abraham
and Kulesza, 2013; Rossetto et al., 2013). However, in both 1,25-
dihydroxyvitamin D3 and PMA treated cells the CHIP-PCR signal is
4 to 10 fold weaker indicative of decreased H3K27me3 at the IE
enhancer. Thus, these results are consistent with our analyses of
IE1 protein expression and suggest that the transition of the MIEP
enhancer region into an open conformation in 1,25-dihydroxyvi-
tamin D3 treated cells is an important prerequisite for the
transition to the lytic phase.
The MIEP contains binding sites for a number of transcription
factors that are responsive to PMA such as NF-κB and CREB (Liu et
al., 2010), but it is unknown if the MIEP would be directly
responsive to 1,25-dihydroxyvitamin D3. We cloned the HMCV IE
promoter from the HCMV-FIX strain into the luciferase reporter
pGL3 so that we could test whether 1,25-dihydroxyvitamin D3,
like PMA would be able to directly stimulate the MIEP-luciferase
reporter gene. We transfected THP-1 cells with pGL3-MIEP, sti-
mulated cells with either 1,25-dihydroxyvitamin D3 or PMA, and
measured luciferase activity. Reporter luciferase was internally
controlled by comparison to constitutively expressed Rennila-
Fig. 5. 1,25-dihydroxyvitamin D3 promotes HCMV early and late gene expression. (A) THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3 (100 nM) or PMA
(80 nM) for 3 days and then infected with HCMV TB40E at a MOI of 10. At the indicated times post-infection, cells extracts were analyzed by western blot for UL44 (early) and
pp65 (late) gene expression. Western blot analyses demonstrated that UL44 and pp65 are robustly expressed in 1,25-dihydroxyvitamin D3 and PMA treated cells. Cell
extracts were also analyzed for actin expression as an internal control. (B) The results of four independent experiments are shown graphically as the ratio of UL44 or pp65 to
actin. (C) THP-1 cells treated as described in panel A were stained for IE and UL44 proteins at days 1 and 4 post-infection and analyzed by ﬂow cytometry. IEþ cells were
gated (left panel in each pair) and then plotted as a function of UL44 expression (right panel in each pair) to determine the fraction of IEþ cells that have entered into the
early phase as assessed by UL44 expression. The results shown are representative of 4 independent experiments. VitD3, 1,25-dihydroxyvitamin D3, npo0.05, nnpo0.01.
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luciferase. Interestingly, the Luciferase assay results demonstrate
that while PMA can directly stimulate MIEP promoter activity,
1,25-dihydroxyvitamin D3 cannot (Fig. 6B). These data are con-
sistent with our ﬂow cytometry data in Fig. 4C, which indicated
that 1,25-dihydroxyvitamin D3 treated cells are more likely to
support IE protein expression but do not exhibit increased levels of
the IE protein on a per cell basis (Fig. 4C). Thus, taken together,
while both 1,25-dihydroxyvitamin D3 and PMA can promote an
open conformation of the MIEP followed by IE protein production
and onset of the lytic phase, the mechanisms used by the two
inducers are not identical as the effects of PMA can at least be
partially explained by a direct effect on the MIEP promoter.
Since the two inducers appeared to not utilize totally over-
lapping mechanisms we investigated whether the effects of 1,25-
dihydroxyvitamin D3 would be additive regarding the onset of
lytic phase. To test this hypothesis, THP-1 cells were treated with
PMA or PMAþ1,25-dihydroxyvitamin D3 prior to infection. Cul-
ture media was harvested at multiple time points post-infection
and viral titers were assessed by plaque assay. Compared to PMA
treated cells, 1,25-dihydroxyvitamin D3 plus PMA did not show an
additive effect as the kinetics and magnitude of the viral growth is
the same (Fig. 7). Thus, while the mechanisms are not totally
overlapping, the convergence of the two compounds on creating
an environment more suitable for IE protein expression seems to
be a necessary prerequisite leading to the onset of the lytic viral
lifecycle.
The differentiation of THP-1 cells triggered by 1,25-dihydroxyvitamin
D3 plays an important role in releasing the restriction on HCMV IE
expression
Based on published studies it is clear that 1,25-dihydroxyvita-
min D3, like PMA, is an inducer of monocyte differentiation and
maturation (Greenberger et al., 1980; Hmama et al., 1999;
Schwende et al., 1996). However, while PMA induces the THP-1
cells to mature into a more highly differentiated macrophage-like
state marked by strong adherence of the cells to plastic, 1,25-
dihydroxyvitamin D3 induces differentiation into a mature mono-
cyte marked by a non-adherent phenotype (Schwende et al., 1996).
Therefore, we wished to investigate the inﬂuence of monocyte
differentiation properties on 1,25-dihydroxyvitamin D3 induced
HCMV replication in the THP-1 model. Consistent with previous
studies (Daigneault et al., 2010; Schwende et al., 1996), we
observed that PMA but not 1,25-dihydroxyvitamin D3 induced
the appearance of a macrophage phenotype with ﬂattened cells
tightly adhered to the ﬂask (Fig. 8A). Immunostaining for the cell
differentiation markers CD14, CD11b, CD36, CD54, and CD68 was
also performed and the results demonstrate that 1,25-dihydrox-
yvitamin D3 consistently induces strong CD14 and moderate
CD11b expression while having little to no effect on CD36, CD54,
and CD68 expression (Fig. 8B and Supplementary Fig. 1). In
contrast, PMA induced moderate levels of CD14, while inducing
robust levels of CD11b, CD36, CD54, and CD68 (Fig. 8B and
Supplementary Fig. 1). These results are entirely consistent with
those of published studies and are further supportive of the
conclusion that 1,25-dihydroxyvitamin D3 induces an intermedi-
ate differentiation phenotype typical of a mature monocyte, while
PMA causes a terminally differentiated phenotype typical of a
macrophage (Kremlev and Phelps, 1997; Kunisch et al., 2004;
Munoz-Pacheco et al., 2012; Schwende et al., 1996). Interestingly,
while PMA induces terminal differentiation and halts cellular
proliferation, 1,25-dihydroxyvitamin D3 treated cells continued
to proliferate in agreement with previous studies (data not shown)
(Schwende et al., 1996).
We then asked whether there was a correlation between 1,25-
dihydroxyvitamin D3 promoted differentiation and onset of lytic
replication. Since 1,25-dihydroxyvitamin D3 appeared to not
directly stimulate MIEP promoter activity, we hypothesized that
the effects of 1,25-dihydroxyvitamin D3 on IE expression might be
delayed and only occur as the cells differentiated into mature
monocytes. To test this postulate, THP-1 cells were treated with
1,25-dihydroxyvitamin D3 for different times (6 h to 3 days) prior
Fig. 6. 1,25-dihydroxyvitamin D3 promotes K27 demethylation of histone H3
associated with the HCMV IE enhancer region, but does not directly stimulate IE
promoter activity. (A) THP-1 monocytes were treated with 1,25-dihydroxyvitamin
D3 (100 nM) or PMA (80 nM) for 3 days and then infected with HCMV TB40E at a
MOI of 10. At 2 days post-infection, chromatin immunoprecipitation was used to
examine the K27 methylation status of histone H3 associated with the HCMV IE
enhancer region. The results presented are derived from 3 independent experi-
ments. (B) MIEP-luciferase activity was assessed in transient reporter gene assays in
the presence of 1,25-dihydroxyvitamin D3 or PMA. MIEP-luciferase activity was
normalized to the internal control renilla luciferase. The results presented are
derived from 3–5 independent experiments performed in duplicate. VitD3, 1,25-
dihydroxyvitamin D3. npo0.05, nnpo0.01.
Fig. 7. 1,25-dihydroxyvitamin D3 and PMA do not function in a cooperative manner to
increase lytic replication. THP-1 cells were differentiated with PMA (80 nM) or PMA
(80 nM) and 1,25-dihydroxyvitamin D3 (100 nM) for one day, and then infected with
HCMV at an MOI of 7. Cell supernatants were harvested at the indicated times post-
infection and viral titers were determined by plaque assay on human foreskin ﬁbroblasts.
The results indicate that 1,25-dihydroxyvitamin D3 and PMA do not function coopera-
tively to enhance HCMV replication in THP-1 cells. The results are derived from
4 independent experiments. VitD3, 1,25-dihydroxyvitamin D3.
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to infection with HCMV (experimental conditions are depicted
graphically in Fig. 9C). Expression of CD14 was monitored
throughout the time course to assess cellular differentiation and
IE positivity was assessed as a measure of the relative ability of the
cells to promote lytic replication. IE expression was measured at
24 h post-infection in all cases. This experimental system enables
us to assess the expression of the differentiation marker CD14 and
the HCMV IE protein in a series of cells in different stages of
maturation. CD14 expression as measured by ﬂow cytometry
peaked at between 1 and 2 days post-stimulation with 1,25-
dihydroxyvitamin D3 (Fig. 9A). Interestingly, we did not observe
signiﬁcant effects of 1,25-dihydroxyvitamin D3 on IE positivity
until 2 days post-stimulation with 1,25-dihydroxyvitamin D3
(Fig. 9B). This ﬁnding is consistent with the conclusion that 1,25-
dihydroxyvitamin D3-induction of lytic HCMV replication corre-
lates with 1,25-dihydroxyvitamin D3 induced cellular differentia-
tion. Moreover, the lack of a signiﬁcant effect of 1,25-
dihydroxyvitamin D3 at early time points argues against a direct
effect of 1,25-dihydroxyvitamin D3 on the MIEP similar to what we
observed in reporter assays in Fig. 6.
Discussion
In this study, we found that 1,25-dihydroxyvitamin D3, a
hormone present in the circulatory system and in many tissues
(Prietl et al., 2013), can promote HCMV replication in primary
peripheral blood monocytes and in THP-1 cells. Our data are
consistent with a mechanism whereby 1,25-dihydroxyvitamin D3
induced HCMV replication involves the induction of monocyte
differentiation. Based on our data, we propose that monocyte
maturation/differentiation induced by 1,25-dihydroxyvitamin D3
leads to a modiﬁcation of histone 3 K27 methylation in the HCMV
IE enhancer region, which results in a conversion to an open
chromatin conformation and induction of IE gene expression.
Moreover, since 1,25-dihydroxyvitamin D3 does not promote cell
cycle arrest and terminal differentiation of monocyte cell lines
in vitro (Schwende et al., 1996), this system represents an inter-
esting paradigm that could be utilized to study reactivation of
virus in model systems. In particular, while previous studies have
shown that PMA differentiated THP-1 macrophages can support
permissive infection, in this study we found that monocytes in the
transition between mature monocytes and macrophage stages,
like the state induced by 1,25-dihydroxyvitamin D3, can also
support permissive infection.
Our work is the ﬁrst to explore the effect of 1,25-dihydrox-
yvitamin D3 on HCMV in myeloid cells. Although the concentra-
tion of 1,25-dihydroxyvitamin D3 used in our study is somewhat
higher than the concentrations found in vivo (Grande et al., 2002),
published studies have demonstrated that in hematopoietic pro-
genitor cells derived from umbilical cord blood, a similar dose of
1,25-dihydroxyvitamin D3 added once a week has the same effects
on monocyte–macrophage differentiation as does physiological
concentrations of 1,25-dihydroxyvitamin D3 supplemented daily
(Grande et al., 2002). In this case the difference between the two
conditions is that high dose treatment causes more rapid
Fig. 8. 1,25-dihydroxyvitamin D3 and PMA induced THP-1 differentiation is phenotypically distinct. (A) THP-1 cells were treated with 1,25-dihydroxyvitamin D3 (100 nM) or
PMA (80 nM) for 3 days and photographed with a Olympus Q Color 5 camera equipped with QCapture Pro Software. (B) Cells treated as in panel A were stained with the
indicated antibodies and analyzed by ﬂow cytometry. Data from four independent experiments is depicted graphically. VitD3, 1,25-dihydroxyvitamin D3. nnpo0.01.
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differentiation and lineage commitment than does physiological
concentrations and thus the high doses like those used in our
study simply facilitate experiments performed in an in vitro
setting.
Although in this research, our main focus is to deﬁne the effect
of 1,25-dihydroxyvitamin D3 on HCMV lytic replication in periph-
eral blood monocytes, an equally attractive question to be
addressed in the future is to ask what effect 1,25-dihydroxyvita-
min D3 has on HCMV replication in hematopoietic progenitor cells
(HPCs), a cell type well-known as a reservoir for HCMV latency
(Goodrum et al., 2002; Maciejewski and St Jeor, 1999). In particular
does 1,25-dihydroxyvitamin D3 treatment of HPCs affect the
ability of HCMV to choose a latent or lytic path and would the
presence of high concentrations of 1,25-dihydroxyvitamin D3
promote lytic reactivation? It is known in the HCMV ﬁeld that
macrophages and mature dendritic cells can support lytic infection
but hematopoietic progenitor cells, myeloid progenitor cells and
monocytes are cell types known to typically establish a latent
infection (Sinclair, 2008; Sinclair, 2010). THP-1 cells treated with
1,25-dihydroxyvitamin D3 do not show a phenotype characteristic
of mature macrophages and therefore, 1,25-dihydroxyvitamin D3
appears to induce a differentiation state in between monocytes
and macrophages. Previously, studies of HCMV in myeloid cells
have focused on hematopoietic progenitor cells (Goodrum et al.,
2007; Maciejewski et al., 1992), myeloid progenitor cells (Cheung
et al., 2006; Kondo et al., 1994), monocytes (Chan et al., 2012;
Keyes et al., 2012b; Stevenson et al., 2014) or macrophages
(Sanchez et al., 2012), and thus our research offers some additional
insight into HCMV replication in cells that are transitioning
between the monocyte and macrophage stages. Although previous
studies suggest that HCMV typically enters the lytic phase in
mature macrophages (Smith et al., 2004; Turtinen and Seufzer,
1994; Weinshenker et al., 1988) our results indicated that cells
transitioning between the monocyte and macrophage stages can
also support lytic infection. HCMV infection itself has been shown
to promote monocyte differentiation but the differentiation pat-
terns triggered by infection alone are not typically capable of
efﬁciently driving lytic infection (Chan et al., 2012; Stevenson
et al., 2014). It is highly possible that there is a differentiation
threshold that is needed to be passed in order to appropriately
kindle a lytic infection. 1,25-dihydroxyvitamin D3 treatment may
prime the cells in the differentiation process, and when infection
provides the appropriate additional differentiation signals, the
threshold is surpassed.
In these studies we examined whether 1,25-dihydroxyvitamin
D3 differentiated monocytes can support lytic infection, but as
mentioned above an important question to ask in the future is
whether 1,25-dihydroxyvitamin D3 may also be involved in the
reactivation of HCMV from latency. Recently, glucocorticoids have
been shown to trigger reactivation of HCMV in primary monocytes
through direct activation of the IE promoter (Van Damme et al.,
2014). Since there are studies showing crosstalk between gluco-
corticoids and 1,25-dihydroxyvitamin D3 (Hidalgo et al., 2011), and
since 1,25-dihydroxyvitamin D3 can enhance glucocorticoid action
in human monocytes (Zhang et al., 2013, 2014), it is reasonable to
speculate that 1,25-dihydroxyvitamin D3 may also be involved in
the regulation of HCMV reactivation or work in concert with
glucocorticoids in this process. Perhaps since the mechanisms of
actions appear to be disparate (glucocorticoids directly on the
MIEP and 1,25-dihydroxyvitamin D3 on cellular differentiation)
these two hormones may work synergistically to affect HCMV
replication and/or reactivation.
Differentiation of monocytes by 1,25-dihydroxyvitamin D3
appears to robustly induce the HCMV lytic phase, but the precise
molecular mechanism(s) that regulates this activity remain
unknown. Based on our studies, we postulate that signaling
activity and gene expression patterns typically triggered by 1,25-
dihydroxyvitamin D3 to drive monocyte maturation/differentia-
tion are required for HCMV lytic infection to proceed. Global
comparison of downstream gene expression induced by 1,25-
dihydroxyvitamin D3, PMA and/or glucocorticoids in monocytes
by microarray or RNA-seq will be helpful to narrow down the list
of candidates, and increase the likelihood of identifying the
essential molecules that regulate this switch.
From a clinical perspective, there are many ongoing studies
showing that 1,25-dihydroxyvitamin D3 or its synthetic analogs
can have anti-cancer effects, and can have beneﬁcial effects on
cardiovascular or autoimmune disease (Delvin et al., 2014; James
et al., 1998; Menezes et al., 2014). Since there is some evidence
supporting a role for HCMV infection in the progression of cancers
(Michaelis et al., 2011; Soroceanu and Cobbs, 2011), cardiovascular
and autoimmune diseases (Caposio et al., 2011; Varani et al.,
2009), our study could prompt questions regarding whether or
not 1,25-dihydroxyvitamin D3 and its synthetic analogs should be
used therapeutically. In addition, the effect of 1,25-dihydroxyvita-
min D3 on HCMV replication in other cell types including
cancer cells is still unknown. Moreover, while 1,25-dihydroxyvi-
tamin D3 can have genomic and non-genomic effects (Norman
et al., 1992), whether those synthetic analogs have the same effect
Fig. 9. The timing and magnitude of 1,25-dihydroxyvitamin D3 induced differ-
entiation of THP-1 monocytes is important for supporting HCMV lytic infection.
(A) THP-1 cells were treated with 1,25-dihydroxyvitamin D3 (100 nM) for indicated
times and CD14 expression was analyzed by ﬂow cytometry. (B) Cells were treated
with 1,25-dihydroxyvitamin D3 for the indicated times prior to infection with
HCMV TB40E. At 24 h post-infection cells were ﬁxed, permeabilized and stained
with HCMV IE antibody mAb810-Alexa488. The results represent ﬂow cytometric
analysis of IE positive cells and are derived from three independent experiments.
(C) Experimental set up for the experiments depicted here. Cells were treated for
variable lengths prior to infection with HCMV TB40E. In all cases IE gene expression
was analyzed at 24 h post-infection. VitD3, 1,25-dihydroxyvitamin D3. nnpo0.01,
nnnpo0.001.
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of 1,25-dihydroxyvitamin D3 on HCMV replication is another
intriguing question to answer and which may provide an important
tool to tease out the speciﬁc pathways involved in lytic induction.
Materials and methods
General reagents
1,25-dihydroxyvitamin D3 and phorbol 12-myristate 13-acetate
(PMA) were purchased from Sigma-Aldrich. APC conjugated anti-
human CD14, anti-human CD11b, anti-human CD54, anti-human
CD36 antibodies and PE conjugated anti-mouse IgG1 antibodies
were obtained from eBioscience. Anti-CMV IE1/IE2 antibody
(mAb810) and an Alexa Fluors 488 conjugated version of
mAB810 were purchased from Millipore. Anti-CMV UL44 antibody
(mAb 25G11, IgG1 isotype) was a kind gift of John Shanley, and
anti-CMV pp65 antibody was obtained from Virusys Corporation.
Cell culture and differentiation of THP-1 cells
THP-1 cells were maintained in RPMI-1640 (Roswell Park
Memorial Institute Institute-1640) supplemented with 10% FBS,
100 IU/ml penicillin and 100 μg/ml streptomycin at 37 1C in 5%
CO2. THP-1 cells were passaged every 3 days to maintain the cell
density between 0.2106 and 1106 cells/ml. Human foreskin
ﬁbroblasts (HFFs) were maintained in DMEM (Dulbecco Modiﬁed
Eagle's Medium) supplemented with 10% Fetal Clone III serum,
100 IU/ml penicillin and 100 μg/ml streptomycin at 37 1C in 5%
CO2. THP-1 cells were treated with 80 nM PMA or 100 nM 1,25-
dihydroxyvitamin D3 for three days to induce cellular maturation/
differentiation.
Propagation and puriﬁcation of virus
The HCMV TB40E-mCherry(3XFLAGUS28) virus was generously
provided by Dr. Christine O' Connor from the Cleveland Clinic
(Miller et al., 2012; O'Connor and Shenk, 2011). This virus was
characterized and demonstrated to grow with similar kinetics and
to similar titers as does HCMV TB40E. To propagate virus, HFFs
were infected with TB40E viruses at an m.o.i. of 0.04. Viral
supernatant was harvested at days 9, 11, and 13 post-infection.
Cell Culture supernatant containing virus was centrifuged at 1800g
for 3 min at 21 1C to remove cellular debris. The clariﬁed super-
natant was overlayed on a 20% D-sorbitol/1 mM MgCl2 cushion
and subjected to ultracentrifugation at 24,000 rpm for 1 h at 21 1C.
Supernatant was decanted, and the viral pellet was resuspended in
RPMI-1640 culture media. Viral supernatant was aliquoted and
stored at –80 1C.
Isolation of monocytes from peripheral blood of normal donors
Blood was diluted 2 fold with Dulbecco's Phosphate-Buffered
Saline (DPBS) containing 2 mM EDTA. Diluted blood was carefully
layered over 15 ml of Ficoll-paques PLUS in a 50 ml conical tube.
Conical tubes were centrifuged at 400g for 30–40 min at 20 1C in a
swinging bucket rotor without brake. After centrifuge, the upper
layer was aspirated, leaving buffy coat containing the mononuclear
cell layer undisturbed at interphase. The buffy coat was transfer to
clean tube, and fresh DPBS with 2 mM EDTA was added to ﬁll the
tubes. The cells were centrifuged at 300g for 10 min at 20 1C. Then
supernatant was carefully removed. In order to remove platelets,
cells were resuspended in 50 ml of DPBS with 2 mM EDTA, and
centrifuged at 200g for 10–15 min at 20 1C. The supernatant was
removed afterward. The wash step was repeated once to further
deplete platelets. Cells were resuspended in 80 ml of buffer (DPBS
containing 0.5% BSA and 2 mM EDTA) per 107 cells. 20 ml of CD14
MicroBeads (Miltenyi Biotec) was added per 107 cells, and cells
were incubated in the cold room (2–8 1C) for 30 min. After
incubation, cells were washed by adding 1–2 ml of buffer (DPBS
containing 0.5% BSA and 2 mM EDTA) per 107 cells, and centri-
fuged at 300g for 10 min. 108 cells were resuspended in 500 ml of
buffer, and passed through LS Column (Miltenyi Biotec). The
columnwas washed 3 times with buffer. The column was removed
from MACS Separator (Miltenyi Biotec), and cells were ﬂushed out
by ﬁrmly pushing the plunger into the column.
Culture and infection of primary peripheral blood derived monocytes
CD14þ monocytes isolated as described above were resus-
pended in RPMI-1640 supplemented with 10% FBS, 100 IU/ml
penicillin and 100 μg/ml streptomycin. Cells were then cultured
in 1,25-dihydroxyvitamin D3 (100 nM), PMA (80 nM) or the
appropriate vehicle control (EtOH or DMSO) for 2 days at 37 1C
in 5% CO2. After 2 days of culture in 1,25-dihydroxyvitamin D3,
PMA or vehicle, viral supernatant was added at a MOI of 10, and
cells were incubated overnight. After overnight incubation with
virus, cells treated with vehicle or 1,25-dihydroxyvitamin D3 were
pelleted by centrifugation, viral inocula were removed, and cells
were treated with 1X trypsin for 5 min to remove attached but un-
internalized virions (O'Connor and Murphy, 2012). Cells were then
resuspended in fresh RPMI supplemented as described above and
cultured for 4–6 days. In the case of the PMA treated cells that
were adhered to the culture plates, viral inocula were aspirated,
cells were washed thoroughly with DPBS, fed with fresh RPMI and
supplements and cultured for 4–6 days.
HCMV infection of THP-1 cells
THP-1 cells were infected with HCMV TB40E-mCherry (3XFLA-
GUS28) at MOIs as indicated in the ﬁgure legends. After the viral
supernatant was added, cells were centrifuged at 21 1C and 1000g
for 30 min to enhance infectivity. After overnight culture, cells
were spun down and the inoculums were removed. Cells were
incubated in 1X trypsin for 5 min to remove attached but un-
internalized virions (O'Connor and Murphy, 2012). The trypsin
reactions were neutralized by adding equal volumes of fresh
culture media. The supernatant is aspirated, and cells were
resuspended in fresh culture media. Because the PMA-
differentiated cells ﬁrmly adhere to the plates, the centrifuge step
is omitted from infection protocol. After overnight culture, culture
media were removed and cells were washed with 1X DPBS, and
fresh media were added to the cells.
Western blot analysis of HCMV gene expression
1106 infected THP-1 cells were lysed in NP-40 cell lysis buffer
(50 mM HEPES pH7.4, 0.5% NP-40, 250 mM NaCl, 20% glycerol,
2 mM EDTA, 100 μM Sodium Orthovanadate, 1 mM Sodium Fluor-
ide, 1X complete Mini protease inhibitor). Cell lysates were
sonicated for 20 s on level 1 using a Sonic Dismembrator Model
100 (Fisher Scientiﬁc). Protein concentrations for each lysate
sample were determined using the Bio-Rad protein assay reagent.
Lysates were mixed with Laemmli sample buffer, and heated at
1001 for 10 min. 30 μg of protein was loaded into each lane for
electrophoresis. Proteins were transferred to nitrocellulose mem-
branes using a semi-dry transfer apparatus (Continental Lab
Products). Membranes were blocked with 5% non-fat dried milk
for 1 h and membranes were incubated with primary antibody at
41 overnight. Membranes were washed 3 times with Tris buffered
saline with Tween-20 (TBST) and then incubated with secondary
antibody for 2 h. Membranes were washed with TBST 3 times and
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subjected to antibody detection using the SuperSignal West Pico
chemiluminescent substrate (Thermo Scientiﬁc). Luminescence
emitted from the membranes was detected by classic blue auto-
radiography ﬁlm BX. Films were developed by Kodak min-R
mammography processor.
MIEP reporter gene construction
The HCMV immediate-early gene promoter (bp 52586–53162
in GenBank entry AC146907.1) was PCR ampliﬁed from FIX-BAC
bacmid DNA using the following primers. HCMV MIEP promoter
forward primer: 50-TAACCCGGGTAGTAATCAATTACGGGG-30, HCMV
MIEP promoter reverse primer: 50-TCGAGATCTCTGACGGTTCAC-
TAAACG-30. PCR ampliﬁcation was performed for 30 cycles, con-
sisting of denaturation at 94 1C for 30 s, annealing at 55 1C for 30 s,
and extension at 72 1C for 30 s. The HCMV MIEP promoter
fragment was cloned into the XmaI and BglII sites of pGL3 and
sequenced to conﬁrm the identity of the MIEP fragment
(Genewiz, Inc).
Luciferase assays
2105 THP-1 cells were plated per well in 24-well plates and
cultured overnight. For each transfection, 410 ng pcDNA3, 60 ng
pGL3-HCMV MIEP, 30 ng phRGTK-renilla and 1.5 μl TransIT-2020
was diluted into 50 μl RPMI-1640 and incubated for 15 min. The
incubated transfection reagent was then added into each well. 4 h
after transfection, vehicle (ethanol or DMSO), 1,25-dihydroxyvita-
min D3 (100 nM), or PMA (80 nM) was added to the designated
wells and the cells were incubated for a further 24 h. Cells were
lysed in 200 μl of 1X passive lysis buffer and 10 μl of the cell lysate
was used in luciferase assay reactions. 50 μl of Fireﬂy-luciferase
substrate was added to cell lysate and luciferase activity was
measured on a Glomax 20/20 luminometer (Promega). 50 μl Stop
and Glow solution was added to each reaction, and luminescence
of the control reporter Renilla-Luciferase was measured. The
Fireﬂy-luciferase reading of vehicle control (ethanol) was divided
by the Renilla-Luciferase reading of vehicle control and that value
was deﬁned as 1. The fold changes were then determined by
dividing the luciferase to renilla ratios of the experimental condi-
tions to the ratio of vehicle control.
Infectious center assays
1105 HFF cells were plated into wells of 12-well plates and
cultured overnight. Infected THP-1 cells or primary monocytes
were harvested at six days post-infection and co-cultured with
HFFs for 2 days. Culture media was then removed and the plates
were washed twice with 1X PBS. Cell monolayers were covered
with overlay media (a 1:1 mixture of 1.5% carboxymethyl cellulose
(Sigma), and 2X MEM supplemented with 20% FCIII serum,
nonessential amino acids, and penicillin-streptomycin) and incu-
bated for another 8 days to allow for plaque development. Cells
were ﬁxed with methanol, stained with 10% Geimsa (Sigma) and
plaques were counted using a dissecting microscope.
Plaque assays
After infection, culture media from each cell sample was
harvested on the indicated days, and 10 μl of culture media was
added to HFF monolayers plated in 12-well plates the previous
day. Virus was adsorbed to HFF monolayers for 3 h, culture media
were removed, and covered with overlay media (a 1:1 mixture of
1.5% carboxymethyl cellulose (Sigma), and 2X MEM supplemented
with 20% FCIII serum, nonessential amino acids, and penicillin-
streptomycin) and incubated for another 8 days to allow for plaque
development. Cells were ﬁxed with methanol, stained with 10%
Geimsa (Sigma) and plaques were counted using a dissecting
microscope.
Flow cytometry
For cell surface marker analyses, cells were harvested and
resuspended in 50 μl of a 0.5% BSA/DPBS solution containing
1:200 dilution of the appropriate APC-conjugated antibody
(CD11b, CD14, etc). Cells were incubated at room temperature
for 1 h. Cells were washed with 0.5% BSA/DPBS solution, resus-
pended in fresh DPBS and analyzed by ﬂow cytometry on a BD
FACSCalibur. For HCMV IE protein staining, cells were harvested,
resuspended in 100 μl DPBS and 1 ml of 70% ice cold EtOH was
added to ﬁx the cells. Fixed cells were washed and permeabilized
with 0.5% BSA/DPBS solution containing 0.5% tween-20. Cells were
then resuspended in 0.5% BSA/DPBS solution containing 1:200
dilution of Alexa488 conjugated anti-HCMV IE antibody, and
incubated at room temperature for 1 h. Stained cells were washed
with 500 μl 0.5% BSA/DPBS solution containing 0.5% tween-20. For
UL44 and IE co-staining, cells were ﬁxed and permeabilized as
above and then resuspended in 0.5% BSA/DPBS solution containing
1:10 dilution anti-HCMV UL44 antibody. Cells were incubated for
1 h at room temperature, washed as described above and then
incubated for 1 h in 0.5% BSA/DPBS solution containing 1:250
dilution of PE-conjugated anti-mouse IgG1 to label the UL44
primary antibody. UL44 stained cells were then washed and
stained for IE proteins as described above. After staining, cells
were resuspended in DPBS and analyzed by ﬂow cytometry.
Semi-quantitative PCR for viral DNA copy number
2105 THP-1 cells were harvested on days 1 and 6 post-
infection, and lysed in 100 μl DNA lysis buffer (Kondo et al., 1994)
containing 20 μg of Proteinase K at 55 1C overnight. Proteinase K
activity was stopped by incubating DNA lysates at 100 1C for
15 min and DNAs were used for semi-quantitative PCR. Primers
for HCMV IE ampliﬁcation: HCMV IE forward 50-ATG-
GAGTCCTCTGCCAAGAGAAAGATGGAC-30, HCMV IE reverse 50-CAA-
TACACTTCATCTCCTCGAAAGG-30 (Bego et al., 2005). Primers used
for GAPDH ampliﬁcation: GAPDH forward 50-GAGCCAAAAGGGT-
CATC-30, GAPDH reverse primer 50-GTGGTCATGAGTCCTTC-30
(Juckem et al., 2008). PCR ampliﬁcation was performed for 30
cycles, consisting of denaturation at 94 1C for 30 s, annealing at
55 1C for 30 s, and extension at 721 for 30 s. Band intensities were
measured by NIH Image software and calculated as a ratio of
HCMV IE DNA over cellular GAPDH DNA.
Chromatin immunoprecipitation
5106 cells were harvested at 2 days post-infection and ﬁxed
in DPBS containing 1% formaldehyde for 10 min at room tempera-
ture. 2.5 M glycine was added to stop the ﬁxation reaction, and
cells were washed in ice cold DPBS. Cells were lysed in cell lysis
buffer (0.5 mM PIPES Ph8, 85 mM KCl, 0.5% NP40, 1X protein
inhibitor cocktail). Nuclei were pelleted by centrifuge and resus-
pended in 500 μl nuclear lysis buffer (50 mM Tris–HCl Ph8, 10 mM
EDTA,1% SDS,1X protein inhibitor cocktail). The lysates were
sonicated for six cycles (30 s on/30 s off) using program 3 on a
Sonic Dismembrator Model 100 (Fisher Scientiﬁc). Lysates were
then diluted 5 fold in IP dilution buffer (0.01% SDS, 1.1% Triton-X
100, 1.2 mM EDTA, 16.7 mM Tris–HCl pH8, 167 mM NaCl, 1X
protein inhibitor cocktail) and pre-cleared with 30 μl sepharose
beads for 2 h at 4 1C. 3 μg of anti-tri-methylated histone 3 antibody
(Millipore) was added into each reaction and rotated overnight at
41C. Protein A/G beads were added to each reaction and incubated
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at 41C for 3 h to capture primary antibody. Protein A/G beads was
pelleted by centrifugation and washed with 1X dialysis buffer
(2 mM EDTA, 50 mM Tris–HCl pH8, 0.2% Sarkosyl, 1X protein
inhibitor cocktail) 3 times. Bound chromatin fragments were
eluted using elution buffer (50 mM NaHCO3, 1% SDS). After elution,
RNase A and NaCl were added to make ﬁnal concentration of
0.083 mg/ml and 0.2 M respectively and the solution was incu-
bated at 65 1C overnight to reverse cross-links. 34 μg of Proteinase
K was added to digest proteins at 45 1C for 2 h. Primers for
ampliﬁcation of MIEP enhancer: Forward primer: 50-TTGGGCA-
TACGCGATATCTG-30. Reverse primer: 50-GCCTCATATCGTCTGT-
CACC-30 (Abraham and Kulesza, 2013). The DNA fragments were
recovered using a Fermentus gel extraction kit and 20 ng of
immunoprecipitated DNA was used for PCR ampliﬁcation. PCR
reaction conditions are the same as mentioned above except were
performed for 36 cycles. The signal from chromatin immunopre-
cipitation samples were normalized to signal from respective
input samples.
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